Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Holdingannounced that the U.S. Bankruptcy Court for the Southern District of Texas has extended the expiration of the ...

Summers Value Partners, an investment management company, released its fourth quarter 2024 investor letter. A copy of the ...

In 2024, the Summers Value Fund LP (“the Fund”) delivered a net1 return of 27.4%. Click here to read the full letter.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Two senior living tech companies focused on AI and senior living resident falls have announced successful fundraising rounds. Technology company SafelyYou ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...